Barclays PLC Grows Stock Position in Voyager Therapeutics, Inc. (NASDAQ:VYGR)

Barclays PLC grew its position in shares of Voyager Therapeutics, Inc. (NASDAQ:VYGR) by 55.8% during the third quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 104,462 shares of the company’s stock after buying an additional 37,398 shares during the period. Barclays PLC owned 0.19% of Voyager Therapeutics worth $612,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds also recently made changes to their positions in the company. China Universal Asset Management Co. Ltd. lifted its holdings in Voyager Therapeutics by 64.1% during the third quarter. China Universal Asset Management Co. Ltd. now owns 10,489 shares of the company’s stock valued at $61,000 after purchasing an additional 4,098 shares during the last quarter. Intech Investment Management LLC bought a new position in Voyager Therapeutics in the 3rd quarter worth approximately $74,000. Victory Capital Management Inc. grew its stake in Voyager Therapeutics by 14.5% in the 2nd quarter. Victory Capital Management Inc. now owns 12,892 shares of the company’s stock valued at $102,000 after buying an additional 1,630 shares in the last quarter. Hsbc Holdings PLC bought a new stake in Voyager Therapeutics during the 2nd quarter valued at $128,000. Finally, Verition Fund Management LLC purchased a new stake in shares of Voyager Therapeutics during the third quarter worth $216,000. Institutional investors own 48.03% of the company’s stock.

Voyager Therapeutics Stock Down 2.5 %

VYGR opened at $5.06 on Friday. The business’s fifty day simple moving average is $5.95 and its 200 day simple moving average is $6.74. Voyager Therapeutics, Inc. has a 52 week low of $4.99 and a 52 week high of $10.66. The stock has a market cap of $276.41 million, a PE ratio of 7.13 and a beta of 0.93.

Voyager Therapeutics (NASDAQ:VYGR) last posted its quarterly earnings data on Tuesday, November 12th. The company reported ($0.16) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.45) by $0.29. The firm had revenue of $24.63 million during the quarter, compared to analysts’ expectations of $12.63 million. Voyager Therapeutics had a return on equity of 8.33% and a net margin of 15.80%. During the same period in the prior year, the business earned ($0.59) EPS. As a group, equities analysts anticipate that Voyager Therapeutics, Inc. will post -0.89 earnings per share for the current year.

Insiders Place Their Bets

In related news, COO Robin Swartz sold 6,500 shares of the stock in a transaction on Monday, December 23rd. The shares were sold at an average price of $5.65, for a total transaction of $36,725.00. Following the transaction, the chief operating officer now owns 112,328 shares of the company’s stock, valued at approximately $634,653.20. This trade represents a 5.47 % decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Over the last ninety days, insiders have sold 10,778 shares of company stock valued at $58,548. 4.53% of the stock is currently owned by corporate insiders.

Analysts Set New Price Targets

Several equities analysts have recently weighed in on the company. Citigroup assumed coverage on Voyager Therapeutics in a research report on Monday, December 2nd. They issued a “buy” rating and a $12.00 price target for the company. Canaccord Genuity Group reaffirmed a “buy” rating and set a $14.00 target price on shares of Voyager Therapeutics in a report on Thursday, November 14th. StockNews.com downgraded shares of Voyager Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, December 13th. Cantor Fitzgerald started coverage on shares of Voyager Therapeutics in a research note on Friday, January 10th. They set an “overweight” rating and a $5.73 price objective for the company. Finally, Leerink Partnrs upgraded shares of Voyager Therapeutics to a “strong-buy” rating in a research note on Wednesday, October 16th. One equities research analyst has rated the stock with a hold rating, eight have given a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, Voyager Therapeutics currently has a consensus rating of “Buy” and an average price target of $15.97.

Voyager Therapeutics Company Profile

Voyager Therapeutics, Inc, a biotechnology company, focuses on the treatment of gene therapy and neurology diseases. The company's lead clinical candidate is VY-TAU01, an anti-tau antibody program for the treatment of alzheimer's disease. Its product pipeline includes superoxide dismutase 1 silencing gene therapy, which is in preclinical trial for the treatment of amyotrophic lateral sclerosis; tau silencing gene therapy, which is in preclinical trial for the treatment of alzheimer's disease; and vectorized anti-amyloid antibody, a gene therapy targeting anti-amyloid for the treatment of alzheimer's disease and is in preclinical trial.